International Isotopes Inc. is Pleased to Announce the Addition of Dr. James R. Miles, to our Drug Product Manufacturing Team
IDAHO FALLS, Idaho, June 15, 2020 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company") is pleased to announce it has hired Dr. James R. Miles, PharmD., ANP as its new Radiopharmaceutical Production Manager. Dr. Miles will be overseeing the production of our I-131 sodium iodide product and our contract manufacturing operations for Progenics Pharmaceuticals Inc.
Dr. Miles completed his Bachelor of Science degree in Biochemistry at U.C. Davis and his Doctorate in Pharmacy at the University of the Pacific. Dr. Miles brings over 20 years of pharmacy and new product development experience to the INIS team. He has worked on development of a range of SPECT and PET products including the successful preparation of several abbreviated New Drug Applications (ANDA's) and Investigational New Drug Applications (IND's). Dr. Miles is well versed in regulatory requirements of both the U.S. Food and Drug Administration (FDA) and the Nuclear Regulatory Commission (NRC) and he has experience with new facility design including cleanroom facilities and installation of a new cyclotron facility.
Steve T. Laflin, President and CEO of the Company, said, "We believe the experience and qualifications of Dr. Miles are a perfect fit for the Company and we are very pleased to have him join the INIS team. Dr. Miles will be an integral part of our start of commercial contract manufacturing of new drug products and to help the Company move other new drugs through our product pipeline."
About International Isotopes Inc.
International Isotopes Inc. manufactures a wide range of calibration and reference standards for nuclear medicine, generic sodium iodide I-131 drug product for hyperthyroidism and thyroid cancer, Cobalt-60 sealed source products, and provides a contract manufacturing of various drug products for clients.
Forward-Looking Statements
Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, but not limited to, the future expectations for new and existing products. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in the Company's filings with the Securities and Exchange Commission at www.sec.gov, including our Annual Report on Form 10-K for the year ended December 31, 2019. Investors, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
FOR MORE INFORMATION CONTACT:
David Drewitz
Creative Options Communications
Investor and Public Relations
david@creativeoptionscommunications.com
www.creativeoptionsmarketing.com
Phone: 972-814-5723
For more information, please visit the Company web site: www.intisoid.com
View original content:http://www.prnewswire.com/news-releases/international-isotopes-inc-is-pleased-to-announce-the-addition-of-dr-james-r-miles-to-our-drug-product-manufacturing-team-301074840.html
SOURCE International Isotopes Inc.
